Abstract:

ABSTRACT The anti-neutrophil cytoplasm antibody associated vasculitis (AAV) is a multisystem autoimmune disorders and the typical histopathology is a focal segmental and necrotizing crescentic glomerulonephritis without immunoglobulin deposition in vessel walls. Immunosuppressive therapy has limited efficacy, and most of patients subsequently have a relapse, and poor in long-term prognosis. Rituximab, an anti-CD20 B cell-depleting therapy, effects on B lymphocytes, and cure AAV. In this paper, we will discuss mechanism of Rituximab action on systemic vasculitis, and summarizes its clinical research progress and value clinical application.

Key words: ANCA-associated vasculitis, Rtuximab, Therapy